---
schema_version: "secwatch.filing_event.v1"
accession: "0000899923-23-000066"
form_type: "8-K"
ticker: "MYGN"
cik: "0000899923"
company_name: "MYRIAD GENETICS INC"
filed_at: "2023-10-11T23:59:59+00:00"
generated_at: "2026-06-10T01:56:15.207858+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Myriad Genetics secures multi-year UnitedHealthcare contract renewal through 2027

## Summary
- New agreement covers tests: MyRisk, MyChoice CDx, BRACAnalysis CDx, Foresight, Prequel, GeneSight, Prolaris.
- Contract effective Jan 1, 2024 to Dec 31, 2027; specific pricing terms not disclosed.
- Company reiterates long-term financial targets announced at Sep 19, 2023 investor day, consistent with this renewal.

## SEC filing metadata
- accession: 0000899923-23-000066
- form_type: 8-K
- ticker: MYGN
- cik: 0000899923
- company_name: MYRIAD GENETICS INC
- filed_at: 2023-10-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899923/000089992323000066/0000899923-23-000066-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899923/000089992323000066/mygn-20231010.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000899923-23-000066
- JSON: https://secwatch.observer/filing/0000899923-23-000066.json
- Plain text: https://secwatch.observer/filing/0000899923-23-000066.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.